You are here: Industry Insights > HemoShear

News List

HemoShear Identifies Novel Drug Target to Treat NASH in Partnership with Takeda americanpharmaceuticalreview
December 31, 2020
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda's discovery portfolio.
SmartZyme spins off protein tech company for a metabolic disease partnership with Hemoshear fiercebiotech
January 02, 2019
SmartZyme BioPharma is spinning off its protein-based therapeutic platform into a new company—dubbed Carnot BioSciences—as part of a collaboration with Hemoshear Therapeutics aimed at rare metabolic diseases.....
Takeda and HemoShear partner to discover new treatments for liver diseases pharmaceufical-technology
October 20, 2017
NASH is a serious, chronic liver disease characterised by inflammation and excessive fat accumulation in the liver, which may lead to fibrosis, cirrhosis, liver cancer and eventually liver failure.